Internal Medicine

Most of the patients in the study were taking concomitant antidepressants and/or antipsychotics, and mood disorders remained stable during treatment with valbenazine.

The Spiration Valve System treats emphysema by blocking air from entering diseased areas of the lung.

Can we learn from the last flu season and prepare for the coming peak influenza activity of the current season?

Healthcare provider employment opportunies have risen 7.1%—an increase from 2017's reported rate of 5%. Where are the jobs in most demand?

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

The pressure for pharma to exist in a permanent state of innovation gets us better therapeutics, but it’s driving up costs unsustainably.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

Outcomes with lacosamide monotherapy for focal seizures in real-world practice were similar to clinical trials but varied with antiepileptic drug history.

Progestin compound segesterone acetate, which would be combined with testosterone, is currently marketed for the use of hormonal contraception, and for the treatment of endometriosis.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Investigators indicated areas of potential improvement for the treatment of new or recurrent C difficile infection.

A small study shows it’s safe to give immunotherapy to patients with HIV who also have cancer.

Old researchers shows children with asthma who experience chronic stress have a heightened inflammatory response profile that puts them at risk for asthma exacerbations.

New research warns that the mechanisms behind HIV latency vary significantly in the blood and the gut.

Research into epilepsy and HRV has been ongoing for more than 30 years, so why hasn’t it been integrated into clinical practice?

Jay Edelberg, MD, PhD, of Sanofi and Robert Sanchez, PhD, of Regeneron shared about the recent ODYSSEY OUTCOMES trial of alirocumab (Praluent) and accompanying cost-effectiveness study.

With a recent FDA approval as the first ever therapy for TD, as well as the first ongoing phase 4 clinical trial, valbenazine use is under close watch by clinicians and specialists.

Patients with tardive syndromes treated with transcranial magnetic stimulation had greater improvement in AIMS scores compared to the sham group.

HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.

Officials are concerned the perpetual cycle of information sharing—by both pro- and anti-vaccination parents—is creating an echo chamber in the US.

The FDA has expanded Novartis’ eltrombopag (Promacta) to include first-line treatment for adults and pediatric patients aged 2 years and older with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST).

In analysis, the therapy plus standard immunosuppressive therapy resulted in a complete response rate 27% greater than that historically observed in patients treated with lone IST, over 6 months.

New results from a pair of phase 3 trials will be used to support AbbVie's anticipated NDA submission in 2019.

Research with more diverse patient populations is needed to confirm this new discovery.

Investigators have found that lowering LDL cholesterol may not be the only way to reduce cardiovascular events—reducing inflammation may be the key to improving outcomes.